254 related articles for article (PubMed ID: 27873460)
21. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
22. Novel Method for Preparation of Site-Specific, Stoichiometric-Controlled Dual Warhead Conjugate of FGF2 via Dimerization Employing Sortase A-Mediated Ligation.
Krzyscik MA; Opaliński Ł; Otlewski J
Mol Pharm; 2019 Aug; 16(8):3588-3599. PubMed ID: 31244217
[TBL] [Abstract][Full Text] [Related]
23. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR; Chan P; Chuh J; Shi X; Nazzal D; Fuh F; McBride J; Ramakrishnan V; de Tute R; Rawstron A; Jack AS; Deng R; Chu YW; Dornan D; Williams M; Ho W; Ebens A; Prabhu S; Polson AG
Mol Cancer Ther; 2013 Jul; 12(7):1255-65. PubMed ID: 23598530
[TBL] [Abstract][Full Text] [Related]
24. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
26. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
27. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
Li H; Yu C; Jiang J; Huang C; Yao X; Xu Q; Yu F; Lou L; Fang J
Cancer Biol Ther; 2016 Apr; 17(4):346-54. PubMed ID: 26853765
[TBL] [Abstract][Full Text] [Related]
28. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
Front Immunol; 2018; 9():1799. PubMed ID: 30123222
[TBL] [Abstract][Full Text] [Related]
29. A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates.
Xu Y; Jin S; Zhao W; Liu W; Ding D; Zhou J; Chen S
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29088062
[TBL] [Abstract][Full Text] [Related]
30. Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway.
Klussman K; Mixan BJ; Cerveny CG; Meyer DL; Senter PD; Wahl AF
Bioconjug Chem; 2004; 15(4):765-73. PubMed ID: 15264863
[TBL] [Abstract][Full Text] [Related]
31. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
[TBL] [Abstract][Full Text] [Related]
32. In situ quantitative bioanalysis of monomethyl auristatin E-conjugated antibody-drug conjugates by flow cytometry.
Zhao WB; Qiu CX; Shen Y; Liu WH; Zhou J; Xu YC; Zhou Z; Chen SQ
Eur J Pharm Sci; 2018 Jul; 120():89-95. PubMed ID: 29727724
[TBL] [Abstract][Full Text] [Related]
33. Sortase A Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody-Drug Conjugates.
Gébleux R; Briendl M; Grawunder U; Beerli RR
Methods Mol Biol; 2019; 2012():1-13. PubMed ID: 31161500
[TBL] [Abstract][Full Text] [Related]
34. Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.
Gébleux R; Stringhini M; Casanova R; Soltermann A; Neri D
Int J Cancer; 2017 Apr; 140(7):1670-1679. PubMed ID: 27943268
[TBL] [Abstract][Full Text] [Related]
35. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
[TBL] [Abstract][Full Text] [Related]
36. A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate.
Xiao D; Zhao L; Xie F; Fan S; Liu L; Li W; Cao R; Li S; Zhong W; Zhou X
Theranostics; 2021; 11(6):2550-2563. PubMed ID: 33456559
[TBL] [Abstract][Full Text] [Related]
37. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
Dela Cruz Chuh J; Go M; Chen Y; Guo J; Rafidi H; Mandikian D; Sun Y; Lin Z; Schneider K; Zhang P; Vij R; Sharpnack D; Chan P; de la Cruz C; Sadowsky J; Seshasayee D; Koerber JT; Pillow TH; Phillips GD; Rowntree RK; Boswell CA; Kozak KR; Polson AG; Polakis P; Yu SF; Dragovich PS; Agard NJ
MAbs; 2021; 13(1):1862452. PubMed ID: 33382956
[TBL] [Abstract][Full Text] [Related]
38. Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.
Stagg NJ; Shen BQ; Brunstein F; Li C; Kamath AV; Zhong F; Schutten M; Fine BM
Regul Toxicol Pharmacol; 2016 Dec; 82():1-13. PubMed ID: 27773754
[TBL] [Abstract][Full Text] [Related]
39. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
[TBL] [Abstract][Full Text] [Related]
40. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]